Liver regeneration after injury: Mechanisms, cellular interactions and therapeutic innovations

Abstract

The liver possesses a distinctive capacity for regeneration within the human body. Under normal circumstances, liver cells replicate themselves to maintain liver function. Compensatory replication of healthy hepatocytes is sufficient for the regeneration after acute liver injuries. In the late stage of chronic liver damage, a large number of hepatocytes die and hepatocyte replication is blocked. Liver regeneration has more complex mechanisms, such as the transdifferentiation between cell types or hepatic progenitor cells mediated. Dysregulation of liver regeneration causes severe chronic liver disease. Gaining a more comprehensive understanding of liver regeneration mechanisms would facilitate the advancement of efficient therapeutic approaches. This review provides an overview of the signalling pathways linked to different aspects of liver regeneration in various liver diseases. Moreover, new knowledge on cellular interactions during the regenerative process is also presented. Finally, this paper explores the potential applications of new technologies, such as nanotechnology, stem cell transplantation and organoids, in liver regeneration after injury, offering fresh perspectives on treating liver disease.

Keywords

interventions / liver injury model / liver regeneration / signalling pathway

References

[1] Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27:R1147-R1151.

[2] Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat Rev Mol Cell Biol. 2021;22:608-624.

[3] Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol. 2021;18:40-55.

[4] Hu Y, Wang R, An Ni, et al. Unveiling the power of microenvironment in liver regeneration: an in-depth overview. Front Genet. 2023;14:1332190.

[5] Paris J, Henderson NC. Liver zonation, revisited. Hepatology. 2022;76:1219-1230.

[6] Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213:286-300.

[7] Li W, Li Lu, Hui L. Cell plasticity in liver regeneration. Trends Cell Biol. 2020;30:329-338.

[8] Rizvi F, Lee Yu-Ri, Diaz-Aragon R, et al. VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. Cell Stem Cell. 2023;30:1640-1657.e1648.

[9] Wang B, Shen H, Wei Y, et al. Balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration. J Hepatol. 2024;80:309-321.

[10] Nicolas CT, Hickey RD, Chen HS, et al. Concise review: liver regenerative medicine: from hepatocyte transplantation to bioartificial livers and bioengineered grafts. Stem Cells. 2017;35:42-50.

[11] Gao Ce, Peng J. All routes lead to Rome: multifaceted origin of hepatocytes during liver regeneration. Cell Regen. 2021;10:2.

[12] Yagi S, Hirata M, Miyachi Y, Uemoto S. Liver regeneration after hepatectomy and partial liver transplantation. Int J Mol Sci. 2020;21.

[13] Wu Yi, Li N, Shu X, et al. Biomechanics in liver regeneration after partial hepatectomy. Front Bioeng Biotechnol. 2023;11:1165651.

[14] Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol. 2004;5:836-847.

[15] Higgins GM. Experimental pathology of the liver. 12. Effect of feeding desiccated thyroid gland on restoration of the liver. Arch Pathol. 1933;16:226-231.

[16] Van Haele M, Snoeck J, Roskams T. Human liver regeneration: an etiology dependent process. Int J Mol Sci. 2019;20.

[17] Gilgenkrantz H, Collin De l’Hortet A. Understanding liver regeneration: from mechanisms to regenerative medicine. Am J Pathol. 2018;188:1316-1327.

[18] Bonnardel J, T’jonck W, Gaublomme D, et al. Stellate cells, hepatocytes, and endothelial cells imprint the kupffer cell identity on monocytes colonizing the liver macrophage niche. Immunity. 2019;51:638-654.

[19] Kawasaki S, Makuuchi M, Ishizone S, Matsunami H, Terada M, Kawarazaki H. Liver regeneration in recipients and donors after transplantation. Lancet. 1992;339:580-581.

[20] Alison MR. Regulation of hepatic growth. Physiol Rev. 1986;66:499-541.

[21] Kwon YJ, Lee KG, Choi D. Clinical implications of advances in liver regeneration. Clin Mol Hepatol. 2015;21:7-13.

[22] Jaeschke H, Akakpo JY, Umbaugh DS, Ramachandran A. Novel therapeutic approaches against acetaminophen-induced liver injury and acute liver failure. Toxicol Sci. 2020;174:159-167.

[23] Chao X, Wang H, Jaeschke H, Ding W-X. Role and mechanisms of autophagy in acetaminophen-induced liver injury. Liver Int. 2018;38:1363-1374.

[24] Lukacs-Kornek V, Lammert F. The progenitor cell dilemma: cellular and functional heterogeneity in assistance or escalation of liver injury. J Hepatol. 2017;66:619-630.

[25] Faccioli LAP, Dias ML, Paranhos BA, Dos Santos Goldenberg RC. Liver cirrhosis: an overview of experimental models in rodents. Life Sci. 2022;301:120615.

[26] Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Investig. 2007;117:539-548.

[27] Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014;60:1090-1096.

[28] Ko S, Russell JO, Tian J, et al. Hdac1 Regulates differentiation of bipotent liver progenitor cells during regeneration via Sox9b and Cdk8. Gastroenterology. 2019;156:187-202.

[29] Russell JO, Lu W-Yu, Okabe H, et al. Hepatocyte-specific β-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes. Hepatology. 2019;69:742-759.

[30] Gu CY, Lee TKW. Preclinical mouse models of hepatocellular carcinoma: an overview and update. Exp Cell Res. 2022;412:113042.

[31] Tao Y, Wang M, Chen E, Tang H. Liver regeneration: analysis of the main relevant signaling molecules. Mediators Inflamm. 2017;2017:4256352.

[32] Tsagianni A, Mars WM, Bhushan B, et al. Combined systemic disruption of MET and epidermal growth factor receptor signaling causes liver failure in normal mice. Am J Pathol. 2018;188:2223-2235.

[33] Kaminsky-Kolesnikov Y, Rauchbach E, Abu-Halaka D, et al. Cholesterol induces Nrf-2-and HIF-1α-dependent hepatocyte proliferation and liver regeneration to ameliorate bile acid toxicity in mouse models of NASH and fibrosis. Oxid Med Cell Longev. 2020;2020:5393761.

[34] Apte U, Thompson MD, Cui S, Liu B, Cieply B, Monga SPS. Wnt/beta-catenin signaling mediates oval cell response in rodents. Hepatology. 2008;47:288-295.

[35] Jin X, Zimmers TA, Jiang Y, Milgrom DP, Zhang Z, Koniaris LG. Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice. Surgery. 2018;163:1264-1271.

[36] Zwirner S, Abu Rmilah AA, Klotz S, et al. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell. 2024;187:1666-1684.

[37] Nejak-Bowen KN, Monga SPS. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol. 2011;21:44-58.

[38] Yang W, Yan He-X, Chen L, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68:4287-4295.

[39] Li N, Kong M, Zeng S, et al. Brahma related gene 1 (Brg1) contributes to liver regeneration by epigenetically activating the Wnt/β-catenin pathway in mice. Faseb J. 2019;33:327-338.

[40] Zhu Y, Qiu Z, Zhang Y, Li B, Jiang X. Partial hepatectomy induced upregulation of SNHG12 promotes hepatocyte proliferation and liver regeneration. Mol Med Rep. 2020;21:1089-1096.

[41] Yang J, Mowry LE, Nejak-Bowen KN, et al. β-catenin signaling in murine liver zonation and regeneration: a Wnt-Wnt situation!. Hepatology. 2014;60:964-976.

[42] Russell JO, Monga SP. Wnt/β-catenin signaling in liver development, homeostasis, and pathobiology. Annu Rev Pathol. 2018;13:351-378.

[43] Aldeguer X, Debonera F, Shaked A, et al. Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. Hepatology. 2002;35:40-48.

[44] Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64:1403-1415.

[45] Sun J-Y, Du L-J, Shi X-R, et al. An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction. Sci Adv. 2023;9:eade4110.

[46] Johnson DE, O’keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234-248.

[47] Park J, Zhao Y, Zhang F, et al. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J Hepatol. 2023;78:45-56.

[48] Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16:448-457.

[49] Roxburgh CSD, Mcmillan DC. Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer. Transl Res. 2016;167:61-66.

[50] Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253-278.

[51] Wen Y, Emontzpohl C, Xu L, et al. Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis. Hepatology. 2023;77:1580-1592.

[52] Huang M, Jiao J, Cai H, et al. C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner. Hepatology. 2022;76:1706-1722.

[53] Ishikawa T, Factor VM, Marquardt JU, et al. Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology. 2012;55:1215-1226.

[54] Péan N, Doignon I, Garcin I, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology. 2013;58:1451-1460.

[55] Doignon I, Julien B, Serrière-Lanneau V, et al. Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. J Hepatol. 2011;54:481-488.

[56] Wang Y-D, Chen W-D, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008;18:1087-1095.

[57] Huang W, Ma Ke, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312:233-236.

[58] Frampton G, Reddy P, Jefferson B, Ali M, Khan D, Mcmillin M. Inhibition of thrombospondin-1 reduces glutathione activity and worsens acute liver injury during acetaminophen hepatotoxicity in mice. Toxicol Appl Pharmacol. 2020;409:115323.

[59] Sivilotti MLA, Yarema MC, Juurlink DN. Treating acetaminophen overdose. Cmaj. 2022;194:E554.

[60] Chidiac AS, Buckley NA, Noghrehchi F, Cairns R. Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease. Expert Opin Drug Metab Toxicol. 2023;19:297-317.

[61] Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018;2:Cd003328.

[62] Viswanathan P, Sharma Y, Gupta P, Gupta S. Replicative stress and alterations in cell cycle checkpoint controls following acetaminophen hepatotoxicity restrict liver regeneration. Cell Prolif. 2018;51:e12445.

[63] Borude P, Bhushan B, Gunewardena S, Akakpo J, Jaeschke H, Apte U. Pleiotropic role of p53 in injury and liver regeneration after acetaminophen overdose. Am J Pathol. 2018;188:1406-1418.

[64] Xu P, Xi Y, Wang P, et al. Inhibition of p53 sulfoconjugation prevents oxidative hepatotoxicity and acute liver failure. Gastroenterology. 2022;162:1226-1241.

[65] Dong S, Ji J, Hu L, Wang H. Dihydromyricetin alleviates acetaminophen-induced liver injury via the regulation of transformation, lipid homeostasis, cell death and regeneration. Life Sci. 2019;227:20-29.

[66] Wen Y, Wang C, Gu J, et al. Metabolic modulation of acetaminophen-induced hepatotoxicity by osteopontin. Cell Mol Immunol. 2019;16:483-494.

[67] Kotulkar M, Paine-Cabrera D, Abernathy S, et al. Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury. Hepatology. 2023;78:1106-1117.

[68] Matchett KP, Wilson-Kanamori JR, Portman JR, et al. Multimodal decoding of human liver regeneration. Nature. 2024;630:158-165.

[69] Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758-2769.

[70] Sehrawat TS, Liu M, Shah VH. The knowns and unknowns of treatment for alcoholic hepatitis. Lancet Gastroenterol Hepatol. 2020;5:494-506.

[71] Kwo PY. Alcoholic hepatitis and its many facets. Clin Liver Dis. 2021;25:xiii-xiv.

[72] Hosseini N, Shor J, Szabo G. Alcoholic hepatitis: a review. Alcohol. 2019;54:408-416.

[73] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038-1048.

[74] Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27:22-41.

[75] Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64:51-68.

[76] Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745-1754.

[77] Mahmood A, Seetharaman R, Kshatriya P, Patel D, Srivastava AS. Stem cell transplant for advanced stage liver disorders: current scenario and future prospects. Curr Med Chem. 2020;27:6276-6293.

[78] Gribben C, Galanakis V, Calderwood A, et al. Acquisition of epithelial plasticity in human chronic liver disease. Nature. 2024;630:166-173.

[79] Raven A, Lu W-Yu, Man TY, et al. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. Nature. 2017;547:350-354.

[80] Pu W, Zhu H, Zhang M, et al. Bipotent transitional liver progenitor cells contribute to liver regeneration. Nat Genet. 2023;55:651-664.

[81] Wu H, Zhou Xu, Fu G-Bo, et al. Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion. Cell Res. 2017;27:709-712.

[82] Tarlow BD, Pelz C, Naugler WE, et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell. 2014;15:605-618.

[83] Huang W-J, Zhou Xu, Fu G-Bo, et al. The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction. Theranostics. 2021;11:5539-5552.

[84] Fu G-Bo, Huang W-J, Zeng M, et al. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens. Cell Res. 2019;29:8-22.

[85] Liu W-M, Zhou Xu, Chen C-Y, et al. Establishment of functional liver spheroids from human hepatocyte-derived liver progenitor-like cells for cell therapy. Front Bioeng Biotechnol. 2021;9:738081.

[86] Segal JM, Kent D, Wesche DJ, et al. Single cell analysis of human foetal liver captures the transcriptional profile of hepatobiliary hybrid progenitors. Nat Commun. 2019;10:3350.

[87] So J, Khaliq M, Evason K, et al. Wnt/β-catenin signaling controls intrahepatic biliary network formation in zebrafish by regulating notch activity. Hepatology. 2018;67:2352-2366.

[88] Martinez Lyons A, Boulter L. NOTCH signalling—a core regulator of bile duct disease? Dis Model Mech. 2023;16.

[89] Boulter L, Govaere O, Bird TG, et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med. 2012;18:572-579.

[90] Lu J, Zhou Y, Hu T, et al. Notch signaling coordinates progenitor cell-mediated biliary regeneration following partial hepatectomy. Sci Rep. 2016;6:22754.

[91] Tang D, Chen Yi, Fu G-Bo, et al. EpCAM inhibits differentiation of human liver progenitor cells into hepatocytes in vitro by activating Notch1 signaling. Biochem Biophys Res Commun. 2020.

[92] Lee S-H, So J, Shin D. Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish. Hepatology. 2023;77:1198-1210.

[93] Kitade M, Factor VM, Andersen JB, et al. Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes Dev. 2013;27:1706-1717.

[94] Pepe-Mooney BJ, Dill MT, Alemany A, et al. Single-cell analysis of the liver epithelium reveals dynamic heterogeneity and an essential role for YAP in homeostasis and regeneration. Cell Stem Cell. 2019;25:23-38.

[95] Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 2013;5:1060-1069.

[96] Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747-2761.

[97] Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211-226.

[98] Cook D, Ogunnaike BA, Vadigepalli R. Systems analysis of non-parenchymal cell modulation of liver repair across multiple regeneration modes. BMC Syst Biol. 2015;9:71.

[99] Fujiyoshi M, Ozaki M. Molecular mechanisms of liver regeneration and protection for treatment of liver dysfunction and diseases. J Hepatobiliary Pancreat Sci. 2011;18:13-22.

[100] Hammoutene A, Rautou P-E. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol. 2019;70:1278-1291.

[101] Hammoutene A, Biquard L, Lasselin J, et al. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. J Hepatol. 2020;72:528-538.

[102] Ito Y, Hosono K, Amano H. Responses of hepatic sinusoidal cells to liver ischemia-reperfusion injury. Front Cell Dev Biol. 2023;11:1171317.

[103] Schoen JM, Wang HH, Minuk GY, Lautt WW. Shear stress-induced nitric oxide release triggers the liver regeneration cascade. Nitric Oxide. 2001;5:453-464.

[104] Preziosi M, Okabe H, Poddar M, Singh S, Monga SP. Endothelial Wnts regulate β-catenin signaling in murine liver zonation and regeneration: a sequel to the Wnt-Wnt situation. Hepatol Commun. 2018;2:845-860.

[105] Duan J-Li, Zhou Zi-Yi, Ruan B, et al. Notch-regulated c-kit-positive liver sinusoidal endothelial cells contribute to liver zonation and regeneration. Cell Mol Gastroenterol Hepatol. 2022;13:1741-1756.

[106] Saviano A, Henderson NC, Baumert TF. Single-cell genomics and spatial transcriptomics: discovery of novel cell states and cellular interactions in liver physiology and disease biology. J Hepatol. 2020;73:1219-1230.

[107] Michalopoulos G. HGF and liver regeneration. Gastroenterol Jpn. 1993;28(4):36-39.

[108] Yin C, Evason KJ, Asahina K, Stainier DYR. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest. 2013;123:1902-1910.

[109] Kitade M, Kaji K, Yoshiji H. Relationship between hepatic progenitor cell-mediated liver regeneration and non-parenchymal cells. Hepatol Res. 2016;46:1187-1193.

[110] Houck KA, Cruise JL, Michalopoulos G. Norepinephrine modulates the growth-inhibitory effect of transforming growth factor-beta in primary rat hepatocyte cultures. J Cell Physiol. 1988;135:551-555.

[111] Olsen PS, Poulsen SS, Kirkegaard P. Adrenergic effects on secretion of epidermal growth factor from Brunner’s glands. Gut. 1985;26:920-927.

[112] Liu W-H, Ren Li-Na, Wang T, Navarro-Alvarez N, Tang Li-J. The involving roles of intrahepatic and extrahepatic stem/progenitor cells (SPCs) to liver regeneration. Int J Biol Sci. 2016;12:954-963.

[113] Shang H, Wang Z, Song Y. Liver progenitor cells-mediated liver regeneration in liver cirrhosis. Hepatol Int. 2016;10:440-447.

[114] Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195-206.

[115] Dedhar S, Williams B, Hannigan G. Integrin-linked kinase (ILK):a regulator of integrin and growth-factor signalling. Trends Cell Biol. 1999;9:319-323.

[116] Martucci N, Michalopoulos GK, Mars WM. Integrin linked kinase (ILK) and its role in liver pathobiology. Gene Expr. 2021;20:201-207.

[117] Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687.

[118] Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44:450-462.

[119] Vannella KM, Wynn TA. Mechanisms of organ injury and repair by macrophages. Annu Rev Physiol. 2017;79:593-617.

[120] Sousa Da Silva RX, Weber A, Dutkowski P, Clavien P-A. Machine perfusion in liver transplantation. Hepatology. 2022;76:1531-1549.

[121] Martins PN, Buchwald JE, Mergental H, Vargas L, Quintini C. The role of normothermic machine perfusion in liver transplantation. Int J Surg. 2020;82s:52-60.

[122] Lascaris B, De Meijer VE, Porte RJ. Normothermic liver machine perfusion as a dynamic platform for regenerative purposes: what does the future have in store for us? J Hepatol. 2022;77:825-836.

[123] Hann A, Nutu A, Clarke G, et al. Normothermic machine perfusion-improving the supply of transplantable livers for high-risk recipients. Transpl Int. 2022;35:10460.

[124] Li M, Fang F, Sun M, Zhang Y, Hu M, Zhang J. Extracellular vesicles as bioactive nanotherapeutics: an emerging paradigm for regenerative medicine. Theranostics. 2022;12:4879-4903.

[125] Córdoba-Jover B, Arce-Cerezo A, Ribera J, et al. Cerium oxide nanoparticles improve liver regeneration after acetaminophen-induced liver injury and partial hepatectomy in rats. J Nanobiotechnol. 2019;17:112.

[126] Chen Y, Shi S, Li Bo, et al. Therapeutic effects of self-assembled tetrahedral framework nucleic acids on liver regeneration in acute liver failure. ACS Appl Mater Interfaces. 2022;14:13136-13146.

[127] Barreto Da Silva T, Dias EA, Cardoso LMDaF, Gama JFG, Alves LA, Henriques-Pons A. Magnetic nanostructures and stem cells for regenerative medicine, application in liver diseases. Int J Mol Sci. 2023;24.

[128] El Baz H, Demerdash Z, Kamel M, et al. Potentials of differentiated human cord blood-derived unrestricted somatic stem cells in treatment of liver cirrhosis. Exp Clin Transplant. 2019;17:251-258.

[129] Zhang J, Lu T, Xiao J, et al. MSC-derived extracellular vesicles as nanotherapeutics for promoting aged liver regeneration. J Control Release. 2023;356:402-415.

[130] Zhang J, Gao J, Li X, et al. Bone marrow mesenchymal stem cell-derived small extracellular vesicles promote liver regeneration via miR-20a-5p/PTEN. Front Pharmacol. 2023;14:1168545.

[131] Zhu L, Wang Q, Guo M, et al. Mesenchymal stem cell-derived exosomes in various chronic liver diseases: hype or hope? J Inflamm Res. 2024;17:171-189.

[132] Driscoll J, Wehrkamp C, Ota Yu, Thomas JN, Yan IK, Patel T. Biological nanotherapeutics for liver disease. Hepatology. 2021;74:2863-2875.

[133] Miyoshi T, Hiratsuka K, Garcia Saiz E, Morizane R. Kidney organoids in translational medicine: disease modeling and regenerative medicine. Dev Dyn. 2019;249(1):34-45.

[134] Kuse Y, Taniguchi H. Present and future perspectives of using human-induced pluripotent stem cells and organoid against liver failure. Cell Transplant. 2019;28:160s-165s.

[135] Nie Y-Z, Zheng Y-W, Ogawa M, Miyagi E, Taniguchi H. Human liver organoids generated with single donor-derived multiple cells rescue mice from acute liver failure. Stem Cell Res Ther. 2018;9:5.

[136] Peng WC, Logan CY, Fish M, et al. Inflammatory cytokine TNFα promotes the long-term expansion of primary hepatocytes in 3D culture. Cell. 2018;175:1607-1619.

[137] Katsuda T, Kawamata M, Hagiwara K, et al. Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity. Cell Stem Cell. 2017;20:41-55.

[138] He J, Cui H, Shi X, et al. Functional hepatobiliary organoids recapitulate liver development and reveal essential drivers of hepatobiliary cell fate determination. Life Medicine. 2022;1:345-358.

[139] Sun L, Hui L. Progress in human liver organoids. J Mol Cell Biol. 2020;12:607-617.

[140] Zhang K, Zhang L, Liu W, et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity. Cell Stem Cell. 2018;23:806-819.

[141] Feng S, Wu J, Qiu W-L, et al. Large-scale generation of functional and transplantable hepatocytes and cholangiocytes from human endoderm stem cells. Cell Rep. 2020;33:108455.

[142] Masuda Y, Yoshizawa K, Ohno Y, Mita A, Shimizu A, Soejima Y. Small-for-size syndrome in liver transplantation: definition, pathophysiology and management. Hepatobiliary Pancreat Dis Int. 2020;19:334-341.

[143] Søreide JA, Deshpande R. Post hepatectomy liver failure (PHLF)—Recent advances in prevention and clinical management. Eur J Surg Oncol. 2021;47:216-224.

[144] Yuan X, Wu J, Sun Z, et al. Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure. Cell Stem Cell. 2024.

[145] Sampaziotis F, Justin AW, Tysoe OC, et al. Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nat Med. 2017;23:954-963.

[146] Tysoe OC, Justin AW, Brevini T, et al. Isolation and propagation of primary human cholangiocyte organoids for the generation of bioengineered biliary tissue. Nat Protoc. 2019;14:1884-1925.

[147] Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science. 2021;371:839-846.

[148] Tandon R, Froghi S. Artificial liver support systems. J Gastroenterol Hepatol. 2021;36:1164-1179.

[149] Saliba F, Bañares R, Larsen FS, et al. Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts. Intensive Care Med. 2022;48:1352-1367.

[150] Starokozhko V, Groothuis GMM. Challenges on the road to a multicellular bioartificial liver. J Tissue Eng Regen Med. 2018;12:e227-e236.

[151] Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure. Curr Opin Crit Care. 2019;25:187-191.

[152] Feng L, Wang Yi, Fu Yu, Li T, He G. Stem cell-based strategies: the future direction of bioartificial liver development. Stem Cell Rev Rep. 2024;20:601-616.

[153] Shi X-L, Gao Y, Yan Y, et al. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes. Cell Res. 2016;26:206-216.

[154] Wang Y, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes. Cell Stem Cell. 2023;30:617-631.e618

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.